Pd-1/Pd-L1 Blockade: Prospectives for Immunotherapy in Cancer and Autoimmunity

Pd-1/Pd-L1 Blockade: Prospectives for Immunotherapy in Cancer and Autoimmunity Publisher Pubmed

Hosseinzadeh R¹ ; Feizisani F² ; Shomali N^{3, 4, 5} ; Abdelbasset WK^{6, 7} ; Hemmatzadeh M^{3, 5} ; Gholizadeh Navashenaq J⁸ ; Jadidiniaragh F^{4, 5} ; Bokov DO^{9, 10} ; Janebifam M³ ; Mohammadi H^{11, 12}

Show Affiliations

1. Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2. Student Research Committee, Sarab Faculty of Medical Sciences, Sarab, Iran
3. Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
4. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
5. Faculty of Medicine, Department of Immunology, Tabriz University of Medical Sciences, Tabriz, Iran
6. Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia
7. Department of Physical Therapy, Kasr Al-Aini Hospital, Cairo University, Giza, Egypt
8. Noncommunicable Diseases Research Center, Bam University of Medical Sciences, Bam, Iran
9. Institute of Pharmacy, Sechenov First Moscow State Medical University, Moscow, Russian Federation
10. Laboratory of Food Chemistry, Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow, Russian Federation
11. Department of Immunology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
12. Noncommunicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran

Source: IUBMB Life Published:2021

Abstract

Immune checkpoint blockade therapy (ICBT) has become a successful cancer treatment approach in the field of cancer immunotherapy. Blockade of programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) with monoclonal antibodies have been known as successful examples of cancer immunotherapy in recent years. Although ICBT has been shown to be beneficial in cancers, such benefits have only been seen in a portion of cancer patients. In this regard, enhancing the therapeutic effects of inhibiting PD-1 and PD-L1 and reducing the side effects of this approach can be considered as a potential approach in a successful ICBT. In this review, we have highlighted new viewpoints regarding improving the therapeutic effect of PD-1 and PD-L1 blockades in cancer therapy. Besides, their expression levels as a biomarker with prognostic value, their role in intestinal microbiota modulation, combination therapy, and immune-related side effects (irAEs) have been discussed. © 2021 International Union of Biochemistry and Molecular Biology.

Related Docs

View other Related Docs

1. Resistance Mechanisms to Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Inhibitors, Expert Opinion on Biological Therapy (2021)

2. Biomarkers for Immune Checkpoint Inhibitors, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)

3. The Evolving Landscape of Predictive Biomarkers in Immuno-Oncology With a Focus on Spatial Technologies, Clinical and Translational Immunology (2020)

4. Pd-1 and Cancer: Molecular Mechanisms and Polymorphisms, Immunogenetics (2018)

5. Tumor Immunology, Clinical Immunology (2022)

6. Review of the Recent Clinical Trials for Pd-1/Pd-L1 Based Lung Cancer Immunotherapy, Expert Review of Anticancer Therapy (2021)

7. Current and Future Perspectives of Pd-1/Pdl-1 Blockade in Cancer Immunotherapy, Journal of Immunology Research (2021)

8. Role of Microbiota-Derived Short-Chain Fatty Acids in Cancer Development and Prevention, Biomedicine and Pharmacotherapy (2021)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (26)

Hamid Reza Mirzaei (2)

Style	Citing Format
MLA	Hosseinzadeh R, et al.. "Pd-1/Pd-L1 Blockade: Prospectives for Immunotherapy in Cancer and Autoimmunity." IUBMB Life, vol. 73, no. 11, 2021, pp. 1293-1306.
APA	Hosseinzadeh R, Feizisani F, Shomali N, Abdelbasset WK, Hemmatzadeh M, Gholizadeh Navashenaq J, Jadidiniaragh F, Bokov DO, Janebifam M, Mohammadi H (2021). Pd-1/Pd-L1 Blockade: Prospectives for Immunotherapy in Cancer and Autoimmunity. IUBMB Life, 73(11), 1293-1306.
Chicago	Hosseinzadeh R, Feizisani F, Shomali N, Abdelbasset WK, Hemmatzadeh M, Gholizadeh Navashenaq J, Jadidiniaragh F, Bokov DO, Janebifam M, Mohammadi H. "Pd-1/Pd-L1 Blockade: Prospectives for Immunotherapy in Cancer and Autoimmunity." IUBMB Life 73, no. 11 (2021): 1293-1306.
Harvard	Hosseinzadeh R et al. (2021) 'Pd-1/Pd-L1 Blockade: Prospectives for Immunotherapy in Cancer and Autoimmunity', IUBMB Life, 73(11), pp. 1293-1306.
Vancouver	Hosseinzadeh R, Feizisani F, Shomali N, Abdelbasset WK, Hemmatzadeh M, Gholizadeh Navashenaq J, et al.. Pd-1/Pd-L1 Blockade: Prospectives for Immunotherapy in Cancer and Autoimmunity. IUBMB Life. 2021;73(11):1293-1306.
BibTex	@article{ author = {Hosseinzadeh R and Feizisani F and Shomali N and Abdelbasset WK and Hemmatzadeh M and Gholizadeh Navashenaq J and Jadidiniaragh F and Bokov DO and Janebifam M and Mohammadi H}, title = {Pd-1/Pd-L1 Blockade: Prospectives for Immunotherapy in Cancer and Autoimmunity}, journal = {IUBMB Life}, volume = {73}, number = {11}, pages = {1293-1306}, year = {2021} }
RIS	TY - JOUR AU - Hosseinzadeh R AU - Feizisani F AU - Shomali N AU - Abdelbasset WK AU - Hemmatzadeh M AU - Gholizadeh Navashenaq J AU - Jadidiniaragh F AU - Bokov DO AU - Janebifam M AU - Mohammadi H TI - Pd-1/Pd-L1 Blockade: Prospectives for Immunotherapy in Cancer and Autoimmunity JO - IUBMB Life VL - 73 IS - 11 SP - 1293 EP - 1306 PY - 2021 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract